You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

ARGATROBAN Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Argatroban patents expire, and when can generic versions of Argatroban launch?

Argatroban is a drug marketed by Amneal Pharms Co, Caplin, Endo Operations, Fresenius Kabi Usa, Gland Pharma Ltd, Hikma Pharm Co Ltd, Hospira, Mylan Institutional, Sandoz, Teva Pharms Usa, Cipla, Accord Hlthcare, and Eugia Pharma Speclts. and is included in sixteen NDAs. There are two patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in ARGATROBAN is argatroban. There are eleven drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the argatroban profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Argatroban

A generic version of ARGATROBAN was approved as argatroban by HIKMA PHARM CO LTD on January 5th, 2012.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for ARGATROBAN?
  • What are the global sales for ARGATROBAN?
  • What is Average Wholesale Price for ARGATROBAN?
Drug patent expirations by year for ARGATROBAN
Drug Prices for ARGATROBAN

See drug prices for ARGATROBAN

Recent Clinical Trials for ARGATROBAN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Veralox TherapeuticsPhase 2
Veralox TherapeuticsPhase 1
CelerionPhase 1

See all ARGATROBAN clinical trials

Pharmacology for ARGATROBAN
Paragraph IV (Patent) Challenges for ARGATROBAN
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
ARGATROBAN IN SODIUM CHLORIDE Injection argatroban 1 mg/mL, 50 mL vials 022434 1 2011-12-16
ARGATROBAN Injection argatroban 100 mg/mL, 2.5 mL vials 020883 1 2007-09-24

US Patents and Regulatory Information for ARGATROBAN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Amneal Pharms Co ARGATROBAN argatroban INJECTABLE;INJECTION 206698-001 Jan 26, 2018 AP RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Eugia Pharma Speclts ARGATROBAN IN SODIUM CHLORIDE argatroban SOLUTION;INTRAVENOUS 209552-001 Nov 27, 2018 RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Hikma Pharm Co Ltd ARGATROBAN argatroban INJECTABLE;INJECTION 203049-001 Jan 5, 2012 AP RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Fresenius Kabi Usa ARGATROBAN argatroban INJECTABLE;INJECTION 201811-001 Mar 23, 2015 AP RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Sandoz ARGATROBAN IN DEXTROSE argatroban SOLUTION;INTRAVENOUS 201743-001 May 9, 2011 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for ARGATROBAN

See the table below for patents covering ARGATROBAN around the world.

Country Patent Number Title Estimated Expiration
European Patent Office 0823430 Procédé pour la préparation de N2-arylsulfonyl-L-arginamides (Method for preparing n2-arylsulfonyl-l-argininamides) ⤷  Sign Up
European Patent Office 0301970 METHOD FOR DISSOLVING ARGININEAMIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM ⤷  Sign Up
Spain 2166937 ⤷  Sign Up
Germany 69707603 ⤷  Sign Up
Japan H0576929 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.